Brief: Idera Pharmaceuticals Gives Clinical Safety Update For Metastatic Melanoma Drug

Aceragen

14/12/2018 12:09

Dec 14 (Reuters) - Idera Pharmaceuticals Inc  IDRA.O :
    * IDERA PHARMACEUTICALS PRESENTS CLINICAL SAFETY AND
EFFICACY
UPDATE FROM THE ILLUMINATE-204 TRIAL OF THE COMBINATION OF
TILSOTOLIMOD AND IPILIMUMAB FOR UNRESECTABLE OR METASTATIC
MELANOMA FOLLOWING FAILURE OF PD-1 INHIBITOR TREATMENT
    * IDERA PHARMACEUTICALS INC - 32.4% OF PATIENTS EVALUABLE
FOR
EFFICACY ACHIEVED PARTIAL RESPONSE OR BETTER; 76.5% OF PATIENTS
ACHIEVED DISEASE CONTROL
    * IDERA PHARMACEUTICALS INC - TUMOR SHRINKAGE OBSERVED IN
BOTH
INJECTED AND UNINJECTED LESIONS, INDICATING AN ABSCOPAL EFFECT
    * IDERA PHARMACEUTICALS INC - COMBINATION REGIMEN CONTINUES
TO BE
GENERALLY WELL TOLERATED

Source text for Eikon:  ID:nGNX9ntksC 
Further company coverage:  IDRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))